Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).
Carcinoma, Renal Cell|Urogenital Neoplasms|Urologic Neoplasms|Kidney Neoplasms
DRUG: motexafin gadolinium
Clinical response rate (CP, PR) to MGd in patients with confirmed progressive RCC (renal cell carcinoma)
Clinical benefit rate (complete response [CR], partial response [PR], stable disease [SD])|Time to progression|Progression-free survival|Overall survival and survival at 6 and 12 months|Duration of clinical response
The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).